FDA Inspection 1100693 — Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited — FEI 3002808311

The FDA completed an inspection of Takeda Pharmaceutical Company Limited on August 9, 2019 in Yodogawa-Ku. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 4 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 9, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Yodogawa-Ku (Japan)

Citations

IDCFRDescription
145221 CFR 211.113(b)Validation lacking for sterile drug products
203121 CFR 211.194(a)Complete test data included in records
357221 CFR 211.100(b)Procedure Deviations Recorded and Justified
360321 CFR 211.160(b)Scientifically sound laboratory controls